Recommendations from Experts in the Management of Adverse Reactions
to ALK Inhibitors (2021 Version) / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 815-828, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-922244
ABSTRACT
Anaplastic lymphoma kinase (ALK) fusion gene, as a tumor driver gene, was crucial for the occurrence and development of non-small cell lung cancer (NSCLC). Recently, targeted ALK fusion gene has become the main treatment method for ALK-positive NSCLC. The first and second generation ALK inhibitors (ALKi), such as crizotinib, ceritinib, alectinib and ensartinib have been approved in China. However, there was no guidance for the management of ALKi adverse reactions. Therefore, this "Recommendations from experts in the management of adverse reactions to ALK inhibitors (2021 version)" has been summarized, led by Lung Cancer Professional Committee of Sichuan Cancer Society and Sichuan Medical Quality Control Center for Tumor Diseases, to provide practical and feasible strategies for clinical ALKi management specification of adverse reactions.
.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Receptor Protein-Tyrosine Kinases
/
Carcinoma, Non-Small-Cell Lung
/
Protein Kinase Inhibitors
/
Crizotinib
/
Lung Neoplasms
Type of study:
Practice guideline
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Lung Cancer
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS